This Year, Mindpeak received its CEMark for BreastIHC, making it the first company with a CE certified Deep Learning solution that can distinguish tumorous and non-tumorous structures on a cellular level. The CE-Mark for in-vitro-diagnostic medical devices confirms that BreastIHC complies with all essential health and safety requirements of all applicable EU directives. It makes the software available to pathology practices across Europe and helps meet the challenge of increasing demand for cancer diagnostics as the number of pathologists declines.

BreastIHC is a plug-and-play solution that enables pathology laboratories to immediately detect, classify and quantify breast cancer cells without the need for complex set-up and calibration procedures. BreastIHC classifies cells into positively stained tumor and unstained tumor cells. One of its great advantages is its ability to differentiate between tumorous and non-tumorous structures, improving the scoring in the tumor microenvironment. "Our algorithm has proven in various tests that it works reliably under a wide range of laboratory conditions and can increase reporting speed and throughput enormously", says Faber.